Trajenta launched in India at fraction of international prices
This article was originally published in Scrip
Executive Summary
Global partners in the diabetes segment, Boehringer Ingelheim and Lilly, are launching Boehringer's once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor, Trajenta (linagliptin 5mg), in India at a fraction of its international prices.